Daniel de Boer, ProQR CEO (via YouTube)
August 11, 2022 10:50 AM EDTUpdated 04:54 PM
R&D

Just months af­ter lay­offs and push­ing eye ther­a­py, Pro­QR to of­fload eye port­fo­lio in piv­ot to RNA-edit­ing

Paul Schloesser

Associate Editor

Near­ly four months af­ter join­ing dozens of oth­er biotechs in lay­ing off em­ploy­ees and trim­ming down its pipeline, Pro­QR is back at it again. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times